Last reviewed · How we verify

T89 high dose — Competitive Intelligence Brief

T89 high dose (T89 high dose) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Traditional Chinese medicine compound / Herbal extract. Area: Cardiovascular.

phase 3 Traditional Chinese medicine compound / Herbal extract Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

T89 high dose (T89 high dose) — Tasly Pharmaceuticals, Inc.. T89 is a traditional Chinese medicine compound that improves myocardial energy metabolism and reduces ischemic injury in cardiovascular disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
T89 high dose TARGET T89 high dose Tasly Pharmaceuticals, Inc. phase 3 Traditional Chinese medicine compound / Herbal extract

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Traditional Chinese medicine compound / Herbal extract class)

  1. Tasly Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). T89 high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/t89-high-dose. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: